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& Manuela Rodriquez1
A broad biophysical analysis was performed to investigate the molecular basis of the neuroprotective 
action of Curcuma longa extracts in Alzheimer’s disease. By combining circular dichroism and electron 
paramagnetic resonance experiments with molecular modeling calculations, the minor components 
of Curcuma longa extracts, such as demethoxycurcumin (2, DMC), bisdemethoxycurcumin (3, BDMC) 
and cyclocurcumin (4, CYC), were analyzed in a membrane environment mimicking the phospholipid 
bilayer. Our study provides the first evidence on the relative role of single curcuminoids interacting with 
Aβ-peptide. When the CYC and curcumin metabolite tetrahydrocurcumin (5, THC) were inserted into 
an anionic lipid solution, a significant modification of the Aβ CD curves was detected. These data were 
implemented by EPR experiments, demonstrating that CYC reaches the inner part of the bilayer, while 
the other curcuminoids are localized close to the membrane interface. Computational studies provided 
a model for the curcuminoid-Aβ interaction, highlighting the importance of a constrained “semi-
folded” conformation to interact with Aβ analogously to the pattern observed in α-helical coiled-coil 
peptide structures. This combined approach led to a better understanding of the intriguing in vitro and 
in vivo activity of curcuminoids as anti-Alzheimer agents, paving a new path for the rational design of 
optimized druggable analogues.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia in 
adults. The mechanisms underlying the disease are currently in question, but the deposition of senile plaques com-
posed by fibrillar aggregates of amyloid β peptide (Aβ) is a characteristic hallmark of the pathology and is con-
sidered fundamental in disease pathogenesis1–4. The main components of the plaques are the peptides Aβ(1–40) 
and Aβ(1–42), which occur as fibrillar aggregates in equilibrium with soluble oligomers and random coil or 
α-helical monomers5–8. Curcuma longa is a Southeast Asian plant, having an orange rhizome with a strongly aro-
matic smell. The rhizome is normally dried and then crushed for gastronomic use as a spice turmeric powder and 
also as a colorant in food (additive E100) and textile industry9. The mixture (MIX) of curcuminoids, obtained as an 
extract from the turmeric powder of Curcuma longa (Fig. 1A), is constituted by the most abundant curcumin (1, 
CUR), demethoxycurcumin (2, DMC), bisdemethoxycurcumin (3, BDMC) and cyclocurcumin (4, CYC), which 
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is present in small amounts. They are provided with important pharmacological activities, such as antioxidant10, 
antiangiogenic11, antiinflammatory12, antiviral13 and anticancer14.
Worldwide comparison of incidence studies promoted by the World Health Organization shows that the inci-
dence rates of AD reported in the populations of South East Asia are lower than in Europe and North America. 
People living in rural compared to urban settings have lower rates of AD: United States ranks 2, Italy 21 and India 
165 among 172 countries15,16, suggesting the existence of undefined protective or risk factors17.
The lower incidence rates of AD in the populations of South East Asia, the main consumers of turmeric, are 
associated with regular curcumin consumption, which is efficacious to counteract the neurophysiological dam-
ages occurring during the disease.
However, the low bioavailability of turmeric components greatly limits its use in therapy. The daily intake of 
a considerable amount of turmeric - up to 3.6 g/die - is converted into nanomolar concentrations in the plasma. 
Pharmacokinetic analysis of curcumin in humans showed that in the peripheral circulation, the main metabolites 
present were curcumin glucuronide and curcumin sulfate18,19, whereas other reduced metabolites resulting from 
the metabolic transformation of curcumin were detected in traces. In particular, after oral administration, the 
analysis of rat plasma concentrations by HPLC revealed the presence of tetrahydrocurcumin (5, THC), hexahy-
drocurcumin (6, HHC) and octahydrocurcumin (7, OHC) (Fig. 1B)20,21, essentially curcuminoids resulting from 
subsequent metabolic reactions of curcumin (1, CUR).
One of the strategies used to overcome the low bioavailability of curcumin involves the co-administration 
of turmeric with piperine, a component of Piper nigrum that inhibits the human enzymes CYP3A4 and 
P-glycoprotein, which are important for the metabolism and transport of xenobiotics and metabolites22. 
Moreover, as the interaction with lipid layers enhances the bioactivity of curcumin23, curcuminoids from turmeric 
rhizome of Curcuma longa, thus containing the four curcuminoids as in the MIX, have been commercialized as 
the highly standardized lecithin-formulated extract Meriva®, developed according to the Indena Phytosome® 
technology. Total curcuminoids absorption was about 29-fold higher for Meriva® than for its corresponding 
unformulated curcuminoids extract24–26.
Considering the implication of Aβ in oligomeric or fibrillar aggregates in the etiology and progress of 
Alzheimer’s disease, thousands of molecules have been screened to identify new substances that can control the 
formation of β amyloid fibrils, either stabilizing the soluble peptide conformation or dissolving aggregates27–30. 
Indeed, among the substances tested for preventing or disaggregating β-amyloid fibrils, curcumin and several 
synthetic curcumin derivatives have been shown to bind Aβ, affecting the process of fibril formation31–36. In 
particular, the analysis of curcumin derivatives highlighted the importance of keto-enol tautomerism, proving 
that the derivatives existing predominantly in the enol-form have higher affinity for Aβ aggregates37–39. Among 
the curcumin derivatives, minor attention has been reserved for the remaining curcuminoids present in turmeric 
extract and their metabolites, although increasing evidence has led to the hypothesis that the activity of each 
of these compounds is determinant for the ultimate biological effect of Curcuma longa extract. Indeed, i) the 
turmeric extract containing optimized proportions of the single curcuminoids and integrated with a given pro-
portion of the reduced metabolite THC exhibits enhanced biological activity40; ii) the turmeric phytocomplex is 
therapeutic despite the unfavorable pharmacokinetic properties of curcumin alone; and iii) metabolites resulting 
from the metabolic transformation of CUR, such as THC, HHC and OHC (Fig. 1B), are themselves biologically 
active20,21.
While the structural interaction between curcumin and Aβ-peptide is known31–36, studies on the possible 
structural interactions with Aβ-peptide of other compounds structurally related to curcumin present in turmeric 
extract or deriving from curcumin metabolism are missing. To overcome this gap, using a combined approach 
including circular dichroism (CD) and electron paramagnetic resonance (EPR) spectroscopy, we analyzed 
the mixture extracted from Curcuma longa (MIX), all the single components (CUR, DMC, BDMC and CYC, 
Fig. 1A) and their metabolites (THC, HHC, OHC Fig. 1B) for their ability to interact with the β amyloid fragment 
Figure 1. (A) Structures of natural curcumin derivatives, curcuminoids, (1–4). (B) Structures of main 
curcumin metabolites (5–7).
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Aβ(25–35). Using an advanced simulation protocol, we acquired data to read all the collected experimental data 
into molecular level.
Many β-amyloid fragments have been studied in vitro and in vivo, and are currently the focus of biophysical 
and computational investigations41. The choice of Aβ(25–35) was based on the evidence that this is the shortest 
fragment of the β-amyloid peptide that forms toxic aggregates, preserving the same activity of the full-length 
Aβ-peptide42–47. Moreover, our previous studies evidenced that, under several different environmental condi-
tions, Aβ(25–35) presents the same conformational behavior as the corresponding fragment in the full length 
Aβ (1–42)46,48. In this respect, it is reasonable to use Aβ(25–35) for testing molecules which may act on the equi-
librium monomer-oligomer-fibril of the full length peptide.
Finally, we decided to undertake our biophysical study in the membrane-mimicking environment represented 
by a liposomal solution of different composition. This choice was dictated by the critical role played by the mem-
brane surface in the β-amyloid toxicity, associated with the curcuminoids’ aptitude for interaction with mem-
branes, enhancing their biological effects23,49–51.
Our study provides the first evidence regarding the relative role of the individual curcuminoid interacting with 
Aβ-peptide in membrane-mimicking environments. Among the examined curcuminoids, only CYC and THC 
can modify the Aβ conformation in the liposome system. Computational studies provide a molecular model for 
curcuminoid-Aβ interaction, suggesting that the constrained “semi-folded” conformation of CYC is suitable for 
interaction with Aβ, reproducing the pattern observed in α -helical coiled-coil peptide structures.
Results
Analysis of curcuminoids. We analyzed the curcuminoids present in Meriva® using a different HPLC elu-
tion system (chromatograms obtained are shown in Supporting Information in Figure 1SI and 2SI). The chro-
matogram obtained under these new conditions showed the presence of CUR (retention time (rt) = 20.44 min), 
DMC (rt = 19.97 min), BDMC (rt = 19.50 min) and another component with the rt of 13.90 minutes. We therefore 
hypothesized that the new peak could correspond to cyclocurcumin. To validate our hypothesis, we embarked on 
the synthesis of cyclocurcumin to fully characterize the new entity via HRMS and NMR and then to evaluate its rt 
by HPLC analysis. The chromatogram obtained (Figure 2SI) was compared with the previous one (Figure 1SI), 
showing that the two had equal retention times. A quantitative analysis of curcuminoids present in the MIX, cal-
culated as the percentage of the area under the curve, was performed, with the following results: 83% CUR, 11% 
DMC, 4% BDMC, and 2% CYC.
The three most abundant natural curcuminoids present in extracts 1, 2, and 3 were obtained by flash chroma-
tography on silica gel using the eluent mixture DCM/MeOH (97:3). Each compound was subsequently charac-
terized via HRMS and 1H-13C NMR. The purity of each isolated compound was assessed by HPLC analysis (see 
Supporting Information).
Synthesis of curcuminoids. Since the quantitative analysis showed 2% cyclocurcumin in the mixture, we 
opted to synthesize this curcuminoid. The general reaction scheme is depicted in Fig. 2A.
Figure 2. (A) Synthesis of cyclocurcumin, CYC (4); reagents and conditions: a) TFA, MW, 100 °C, 4 min, 10%. 
(B) Synthesis of THC (5); reagents and conditions: b) H2 (1 atm), Pt/C, MeOH, r.t., 1 h, 77%. (C) Synthesis of 
HHC (6) and OHC (7); reagents and conditions: c) H2 (6.8 atm), Pt/C, MeOH, r.t., 13 h; 6, HHC (37%); 7, OHC 
(55%).
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Several attempts were made to obtain CYC (see Table SI1 in Supporting Information). We first reproduced the 
acid-catalyzed cyclization of curcumin as reported by Kiuchi and coworkers52 using benzene and TFA (trifluoro-
acetic acid) for 65 h in the dark. The reported reaction yield is 20%; nevertheless, in our hands, the same reaction 
never provided a yield higher than 5%, probably because of the difficulties shown in the purification process. We 
attempted to modify the acidity of the reaction medium by replacing the TFA with TfOH (trifluoromethanesul-
fonic acid) (Table 1SI); however, the yield did not improve. A reduction of both the reaction time and the amount 
of by-products was achieved using microwave-assisted synthesis in benzene. The best result was obtained through 
a solvent-free reaction, performing just one 4 min MW run using TFA at 100 °C. Under these conditions, the 
reaction yield was 10%, barely sufficient to accumulate the desired quantities despite being completed in only a 
few minutes.
Among the metabolites formed after the administration of curcumin, the most interesting are THC, HHC and 
OHC, which are obtained after the reduction in vivo of curcumin. In all these compounds, the extended conju-
gation is lost, and in the case of HHC and OHC, the keto-enol tautomerization is lost as well. This behavior was 
very interesting as a way to assess the actual importance of tautomerism in the pharmacodynamics of curcumin.
The synthesis of these three metabolites was conducted through catalytic hydrogenation, suitably varying the 
reaction time and H2 pressure53. THC was obtained in 77% yield using H2 (1 atm), Pt/C, and MeOH for 1 h at 
room temperature (Fig. 2B).
HHC and OHC were obtained in a 40:60 mixture using higher hydrogen pressures and longer reaction times 
in a Parr® apparatus (6.8 atm H2, Pt/C, MeOH at room temperature for 13 h (Fig. 2C). HHC and OHC were 
obtained with yields of 37% and 55%, respectively.
Circular dichroism analysis. Biological and biophysical experiments show that curcumin can interact with 
Aβ-peptide in soluble or fibrillar form31–36. The correlation between the pathological role of Aβ-peptide and its 
interaction with the neuronal membrane is well established23,49–51,54. The phytosomal formulation of curcumi-
noids (Meriva®) is proven to enhance the biological action of curcumin in terms of plasmatic availability24,26 and 
penetration in tissues characterized by amyloid plaque deposition55.
To test the hypothesis that all these actions might share a common biophysical mechanism related to the 
interaction of Aβ with curcumin at the biomembrane, we analyzed Aβ(25–35) in liposomal solution by CD 
spectroscopy (Fig. 3A,B), focusing on the variation of its conformation in the presence of the individual cur-
cuminoids shown in Fig. 1. We chose as the liposome systems small unilamellar vesicles (SUV) composed of 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and/or 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) 
(DOPG). Varying the lipid constituents can suitably modulate the liposome composition. The constituents can 
differ in the length and number of the methylene chains, as well as the polarity and charge of the polar heads. 
Given the importance of the superficial charge in driving the behavior of the molecules on the membrane sur-
face, we decided to record CD spectra in three different liposome solutions distinguished by different superficial 
charges. DOPC is characterized by a zwitterionic membrane surface, DOPG by a negatively charged surface, and 
DOPC/DOPG (90/10 molar ratio) by a zwitterionic surface doped with a small amount of negative charge.
Aβ(25–35) was obtained in complete monomeric form, according to the defibrillating procedure described by 
Zagorski56. CD spectra of monomeric Aβ(25–35) (100 μ M solution) were recorded in DOPC, DOPG and DOPC/
DOPG liposomal solution (200 μ M solution) (see Supporting Information). The qualitative and quantitative anal-
ysis of CD curves (DICHROWEB online server)57 indicates that Aβ(25–35), in all the examined solutions, exists 
in an equilibrium of random coil (slightly predominant), α -helix, and β -sheet conformations (Fig. 3B). CD spec-
tra recorded in DOPC and DOPC/DOPG liposomal solutions after the addition of curcuminoids show no signif-
icant modification of the Aβ(25–35) conformation in DOPC and DOPC/DOPG liposome solution. Conversely, 
Aβ(25–35) in DOPG solution, containing CYC and THC, undergoes a marked increase in α -helix structures, as 
shown by the quantitative evaluation of the CD spectra reported in Fig. 3A.
To estimate the proportions in which these conformational modifications were attributable to direct Aβ(25–35)/ 
curcuminoid interaction or were mediated by the phospholipid bilayer, we recorded CD spectra in mixture of 
water/organic solvents. An exhaustive conformational analysis of Aβ(25–35) in a hexafluoro-2-propanol (HFIP)/
water mixture containing different proportions of organic solvent and water was previously conducted in our 
lab45. This study proved the ability of HFIP to stabilize monomer helical Aβ(25–35) conformations. Thus, pro-
ceeding from our previous experience, we recorded CD spectra of Aβ(25–35) in HFIP/water 80/20 v:v in the 
absence and in the presence of CYC and THC. Analysis of the CD spectra shows that, even in these conditions, 
CYC modifies the conformational behavior of Aβ(25–35) (Fig. 3C,D), whereas THC induces only modest modifi-
cations of the CD spectra. These results indicate that the ability of CYC to destabilize the conformational arrange-
ment of Aβ(25–35) is due to a direct CYC-peptide interaction instead of a mediated mechanism involving the 
lipid membrane, as in the case of THC.
EPR experiments. The CD experiments suggest that a significant perturbation of Aβ(25–35) conforma-
tional preferences could be induced by the peptide interaction with CYC and THC. These interactions are modu-
lated by the presence of lipid membranes in the case of THC and MIX, whereas CYC can modify the behavior of 
Aβ(25–35) directly. To investigate this effect more deeply, we performed EPR analysis using experimental condi-
tions consistent with the ones adopted for CD analysis. EPR spectroscopy requires the presence of unpaired elec-
trons in the system to be investigated. To study microstructured systems, specific components can be selectively 
labeled with radical moieties, thus making it possible to obtain detailed information on the specific site where 
the label is positioned. In this work, we have used phospholipids specifically spin-labeled at different positions 
along the acyl chain. 5-PCSL is labeled very close to the hydrophilic head-group, thus allowing observation of the 
behavior of the bilayer region just below the interface. In contrast, 14-PCSL allows analysis of the properties of 
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the inner part of the bilayer hydrophobic core58. Using these two spin-labels, we focused on two different aspects 
of the systems under consideration in this work. First, we studied the interaction of curcumin and its analogues 
with the lipid membranes formed by DOPC, DOPG and DOPC/DOPG (90/10 molar ratio); second, we analyzed 
the effects of these ligands on the interaction of the Aβ(25–35) peptide with the lipid bilayers. The 5-PCSL spec-
trum in DOPC bilayers (Fig. 4A, solid line) shows a clearly defined axially anisotropic behavior, as detectable by 
the splitting of the low- and high-field lines, indicating an ordered organization of the outer segments of the lipid 
acyl chains. The 14-PCSL spectrum, registered in the same system, shows an almost isotropic three-line lineshape 
(Fig. 4B, solid line).
Very similar results were obtained for the DOPG and DOPC/DOPG (90/10 molar ratio) bilayers (spectra not 
shown). This evidence indicates, for all the considered lipid systems, an increase flexibility in terms of the seg-
mental chain mobility moving inward from the polar head-groups to the inner hydrophobic core, as expected for 
membranes in the liquid-disordered (Ld) crystalline state59. To quantitatively analyze the spectra, the values of the 
outer hyperfine splitting, 2Amax, were determined by measuring the difference between the low-field maximum 
and the high-field minimum, using a home-made MATLAB-based software routine. In general, 2Amax is depend-
ent on both the amplitude (i.e., order) and the rate of chain rotational motion and is therefore a useful parameter 
for characterizing chain dynamics, as determined by local ordering, in phospholipid membranes60. It is a sensitive 
means for detecting and quantifying lipid bilayer interactions with guest molecules, as previously demonstrated61. 
The 2Amax value is much higher for 5-PCSL than for 14-PCSL (approximately 51 G vs. 32 G) and is quite insen-
sitive to the lipid charge (for 2Amax values for 5-PCSL and 14-PCSL in DOPC, DOPG and DOPC/DOPG (90/10 
molar ratio) bilayers (Table 2SI in Supporting Information). In the presence of curcumin, the anisotropy of the 
5-PCSL spectrum in DOPC increases slightly but significantly, as shown by Fig. 4A, dashed line. The anisotropy 
increase indicates a motional restriction of the spin-labeled chain and is usually related to the presence of guest 
molecules61. In contrast, the 14-PCSL spectrum remains almost unaffected (Fig. 4B). These results indicate that 
curcumin interacts with the bilayer, positioning close to the head-group region with a limited but still detectable 
intercalation among the outer segments of the lipid acyl chains. This conclusion is in reasonable agreement with 
the “surface association” of curcumin proposed by Sun62, while confirming a certain degree of internalization as 
found by Barry23,54.
Qualitatively similar effects were observed for DOPG and DOPC/DOPG (90/10 molar ratio) bilayers, pertur-
bation being slightly higher for the anionic lipid system. Consistently, the 2Amax values reported in Table 2SI show 
an increase for 5-PCSL, while remaining almost constant in the case of 14-PCSL. The analogues of curcumin 
Figure 3. (A) CD spectra of Aβ(25–35) in DOPG vesicles in the absence and the presence of ligands MIX,  
(B) Secondary structure quantification of Aβ(25–35) in DOPG vesicles in the presence of curcuminoid 
compounds. (C) CD spectra of Aβ(25–35) in HFIP/water mixture in the absence and the presence of ligands 
MIX, (D) Secondary structure quantification of Aβ(25–35) in HFIP/water mixture in the presence of 
curcuminoid compounds.
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considered in this work cause variations in the 5-PCSL and 14-PCSL 2Amax values that are qualitatively similar to 
the ones observed for CUR (see Table 2SI).
To easily compare the effects of the various ligands on the bilayer structure, Fig. 4 (panels C–E) reports the 
2Amax variation upon ligand inclusion in all the considered systems for both spin-labels. In the case of 5-PCSL, the 
variation is positive in all cases and higher for the DOPG bilayers.
In the case of 14-PCSL, the 2Amax variations are almost negligible. Thus, it can be concluded that all CUR 
derivatives present a marked tendency to interact with the bilayers, shallowly penetrating between the lipid acyl 
chains. The differences between the various ligands are not dramatic, even though CYC seems more effective in 
perturbing the membrane inner layer. Indeed, for this ligand, even the 14-PCSL 2Amax in anionic membranes is 
slightly but significantly perturbed. Then, we turn our attention to the interaction of the Aβ peptide with lipid 
membranes, analyzing the extent to which it is affected by the presence of curcumin and its analogues.
The addition of Aβ(25–35) significantly increases the anisotropy of the 5-PCSL spectrum in DOPC (see 
Fig. 4A, dotted line). Accordingly, the peptide causes a clear 2Amax increase (Table 2SI), i.e., the mobility of the 
spin-labeled chains decreases through the interaction of the peptide with the membrane. In contrast, the addition 
of Aβ(25–35) to DOPC bilayers does not causes any change in the 14-PCSL spectrum (Fig. 4B). This evidence 
indicates that Aβ(25–35) is inserted in the bilayer positioning between the outer part of the hydrophobic core 
and the external hydrophilic layer. A similar solubilization site was already observed in other lipid systems58,63. 
When Aβ(25–35) is added to the lipid bilayers in the presence of curcumin or its analogues, the 5-PCSL spectrum 
Figure 4. EPR spectra of 5-PCSL (A) and 14-PCSL (B) in lipid bilayers composed of DOPC or DOPC and 
CUR, in the absence and in the presence of Aβ(25–35). Red lines are guides for the eye, highlighting the shifts of 
the low-field maximum and high-field minimum. Increase in outer hyperfine splitting of 5-PCSL and 14-PCSL 
in DOPC, DOPG and DOPC/DOPG 90/10 bilayers upon inclusion of ligands (CUR, DMC, BDMC, MIX, CYC, 
THC, HHC and OHC) in the lipid formulation (panels C,E) and upon addition of Aβ(25/35) to the system 
(panels D,F).
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is much less affected, and in some cases, no variation is observed (see Table 2SI). To better visualize the effects 
of the various ligands on the peptide-bilayer interaction, Fig. 4 (panels D,F) shows the 2Amax variations of the 
ligand-bilayer systems upon the addition of Aβ(25–35).
Inspection of the figure indicates that the presence of ligands at the bilayer interface hinders any membrane 
penetration of the peptide. We propose that the accumulation of a layer of bound curcumin (or its analogues) 
at the lipid membrane interface reduces the accessibility and number of binding sites for Aβ on the membrane. 
Moreover, curcumin on the membrane surface can reduce Aβ–membrane interaction by altering the lipid 
head-group charge and reducing the favorable electrostatic interactions between Aβ and lipid head-groups64. 
The inspection of Fig. 3 clearly shows that all the ligands behave similarly, with the possible exception of CYC in 
DOPG membrane: in this case, the further 2Amax increase due to Aβ(25–35) suggests that the peptide preserves 
a detectable ability to interact with the bilayer even in the presence of the ligand. This evidence supports the 
hypothesis that DOPG membranes create a perfect environment to enhance Aβ(25–35) interaction with CYC.
Molecular Modeling Studies. To relate the obtained CD and EPR results to the different structural features 
of the tested curcuminoids, a molecular modeling study was conducted. In particular, the structural features 
responsible for the interaction with Aβ(25–35) were investigated.
First, a comprehensive conformational analysis was performed on all possible tautomers of i) CUR, which is 
unable to affect the Aβ(25–35) conformational equilibrium either in a liposomal environment or in HFIP/water 
solution; ii) THC, which affects the Aβ(25–35) conformational equilibrium only in a liposomal environment; 
and iii) CYC, which perturbs the conformational behavior of Aβ(25–35), both, in DOPG and HFIP/water solu-
tion. The conformational space was sampled using a protocol including molecular dynamics (MD) simulations 
followed by molecular mechanic (MM) optimization, mimicking the polarity of a water medium (ε = 80*r). The 
identified minima were then subjected to full geometry optimization using the semi-empirical PM7 (MOPAC) 
method (ε = 1; for details see Experimental Section), thus obtaining a new set of conformers using a dielec-
tric constant similar to the one for the highly hydrophobic membrane environment65. In this regard, it must be 
emphasized that only qualitative considerations can be deduced by comparing the results obtained from MM 
(ε = 80*r) and PM7 (ε = 1) calculations.
The MM and PM7 conformers obtained were ranked by their potential energy values (i.e., Δ E from the global 
energy minimum) and classified into different families based on the values of their torsional angles. Then, the 
distance between the centroids of the two aromatic rings was calculated (d1; Figures 3SI, 5SI–8SI; Tables 3SI–6SI). 
According to this latter parameter, the conformers were further classified as i) “folded” when d1 was ≤ 5 Å, ii) 
“semi-folded” when d1 was > 5 Å and < 9 Å, and iii) “extended” when d1 was ≥ 9 Å. Finally, the occurrence rate of 
each conformational family was calculated (Table 1 and Tables 3SI–6SI).
The results showed peculiar conformational features for each of CUR, CYC, and THC. The conformational 
behavior of CUR differed in the two tautomeric forms. Indeed, the conformers of the CUR-diketone form are dis-
tributed in two main conformational families: the “extended” and the “folded” (Tables 1 and 3SI; Figures 3SI–4SI), 
with the latter including the global minimum (GM) conformer. In particular, comparing PM7 with MM shows 
an increase in the number of “folded” conformers, i.e., presenting the two aromatic rings interacting with each 
other, and a concomitant decrease in the “extended” conformers can be observed. This result is due to the higher 
degree of accuracy of semi-empirical vs. MM methods in calculating electronic parameters, as well as to the fact 
that electrostatic interactions are expected to increase in non-polar (low dielectric) solvent.
In contrast, in the keto-enol form of CUR, the conjugation of the double bonds extending from one aromatic 
ring to the other and the formation of a hydrogen bond between the ketone oxygen and the hydrogen of the enol 
function (Fig. 5A and B) strongly constrain the conformational freedom of the structure. Consequently, all CUR 
keto-enol conformers belong to the “extended” conformational family, resulting from both the MM and PM7 
calculations (Tables 1 and 4SI; Figure 5SI). In detail, the PM7 low-energy conformers (within 5 kcal/mol from 
the GM) of the keto-enol form of CUR showed a specific preference for two sets of conformations, differing 
only for the value of the torsional angle τ 1, herein named conf I (τ 1 = ∼ 180°) and conf II (τ 1 = ∼ 0°) (Fig. 5A 
and B; Table 4SI). These results are consistent with the ones obtained from the analysis of the experimentally 
determined structures of CUR (all in the keto-enol form) deposited in the Cambridge Structural Database (CSD) 
(Table 7SI). Indeed, CUR can assume either conf I (CSD codes: AXOGIE, AXOGOK, BINMEQ06, BINMEQ07, 
and BINMEQ08) or conf II (CSD codes: BINMEQ, BINMEQ01, BINMEQ02, BINMEQ03, BINMEQ04, and 
BINMEQ05), as shown by our conformational analysis.
The presence of the dihydropyran-4-one ring in CYC determined a different conformational behavior from 
the observation for CUR tautomers. Indeed, all CYC conformers, both MM and PM7, fall into the “semi-folded” 
Cmp
MM PM7
Folded Semi-folded Extended Folded Semi-folded Extended
CUR (diketone) 22.0 27.5 50.5 65.5 19.5 15
CUR (keto-enol) 0.0 0.0 100 0.0 5.0 95
CYC 0.0 100 0.0 0.0 100 0.0
THC (diketone) 39.5 47.0 13.5 56.0 35.0 9.0
THC (keto-enol) 16.0 59.5 24.5 37.5 45.0 17.5
Table 1.  Calculated occurrence rates (%) of MM and PM7 conformers presenting “folded”, “semi-folded” 
and “extended” conformation.
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conformational family (Table 1 and Figure 6SI). Overall, CYC showed four possible subfamilies of conformers, 
differing for the values of the torsional angles τ 1, τ 2, and τ 3 and characterized by d1 ranging from 7.00 to 9.66 Å 
(conf I–IV in Fig. 5C–F and Table 5SI).
THC shows yet another conformational preference compared either to CUR or CYC. According to the results 
of our analysis, THC conformers fall into all three conformational families regardless of the tautomeric form 
or the computational method used (Table 1; Figure 9SI; Table 6SI). However, either in the diketone or in the 
keto-enol form, the “folded” conformation is strongly stabilized by the formation of a hydrogen bond between 
the hydroxyl groups of the two aromatic rings (Figure 9SI). This intra-molecular H-bond may compete with the 
formation of H-bond interactions with solvent molecules, which are not treated explicitly in this simulation. 
Thus, it is likely that the actual conformational behavior of THC strongly depends on the chemical environment.
Furthermore, to investigate the experimentally observed interaction between Aβ(25–35) and CYC in HFIP/
water 80/20 solution, we performed a dynamic molecular docking simulation on the CYC-Aβ(25–35) complex, 
mimicking the polarity of the media with a dielectric constant of 30*r. To fully explore all possible binding sites/
modes during the dynamic docking procedure, the binding site was defined as the whole peptide, and all rotatable 
bonds of CYC and Aβ(25–35) were left fully free to move. A force constant of 10 kcal/mol/Å2 was only applied on 
the backbone hydrogen bonds of (Asn27-Leu34) to avoid unrealistic results during the annealing simulation (for 
details, see the Experimental Section). First, a Monte Carlo/minimization approach for the random generation of 
a maximum of 20 acceptable complexes was used. To ensure a wide variance of the input structures to be mini-
mized afterward, an energy tolerance value of 106 kcal/mol from the previous structure was used. After the energy 
minimization step, the energy test, with an energy range of 50 kcal/mol, and a structure similarity check (rms 
tolerance = 0.3 kcal/A) was applied to select the 20 acceptable structures. To test the thermodynamic stability of 
the resulting docked complexes, these latter were then subjected to simulated annealing (SA) calculations. In SA 
the temperature is altered in time increments from an initial (500 K) to final (300 K) temperature. The tempera-
ture of 500 K was applied with the aim of surmounting torsional barriers, thus allowing a full rearrangement of 
the ligand and the peptide (see Experimental section for details).
The resulting complexes were analyzed and ranked by their conformational and interaction energy values 
(Table 8SI). On twenty Monte Carlo generated structures, only twelve (Figure 10SI) still present CYC bound to 
Aβ(25–35) peptide after SA calculations. Interestingly, just one of these twelve SA complexes preserves the same 
binding mode resulting from Monte Carlo docking procedure, showing thermodynamic stability (Complex 1, 
Figure 10SI). Importantly, this complex also resulted to be the lowest energy complex and the one characterized 
by the most favorable interaction energy (Table 8SI). Such results strongly suggest that Complex 1 is representa-
tive for a stable and rather specific binding mode of CYC to Aβ (25–35) peptide (Fig. 6A and B).
Interesting data provided by our docking results showed that the calculated binding mode of CYC to Aβ(25–35) 
resembles the canonical packing of the α -helical coiled-coil dimerization motif, where the side-chains of the “a” 
and “d” residues of two facing heptad repeat motifs interact with each other (Fig. 6C)66. In fact, in the consensus 
sequence of the heptad repeat motif, the “a” and “d” positions are occupied by hydrophobic residues (one of which 
can be replaced by an asparagine), favoring the formation of coiled-coil structures, where the i, i + 4, and i + 7 
residues of a helix interact with the equivalent residues of another helix. As evidenced by the superimposition 
reported in Fig. 6C, CYC can mimic the interactions performed by such residues. In particular, the two substi-
tuted phenyl rings (d1 = 8.85 Å) can reproduce the orientation of the hydrophobic side chains of the i and i + 7 
residues (distance from the side chain centroids = 8.20 Å), and at the same time, the dihydropyran-4-one ring and 
the ethylene bridge overlap with the central i + 4 residue (Fig. 6C).
Taken together our computational results support the hypothesis that CYC targets heptad repeat motifs like 
the one found in Aβ(25–35) (Fig. 6C), whose structure is preserved in full length Aβ(1–42) and which is part of 
Figure 5. PM7 lowest energy conformers of i) keto-enol CUR conf I (A; orange) and conf II (B; green) and ii) 
CYC conf I (C; pink), conf II (D; cyan), conf III (E; gray), and conf IV (F; yellow). The conformers are displayed 
as ball & stick models and colored by atom type: O, red; H, white. Hydrogen bonds are highlighted with a black 
dashed line.
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the extended heptad repeat motif identified as responsible for the dimerization of APP in micellar environment 
(Figure 11SI)67.
Discussion
A great deal of evidence shows that curcumin and several synthetic curcumin derivatives bind beta amyloid 
peptides, affecting the process of fibril formation31–36. In light of the well-documented pharmacological effects, 
including the neuroprotective effect exerted by the less abundant curcuminoid molecules in the Curcuma Longa 
extract, we studied these molecules for their ability to affect the conformational arrangement of Aβ(25–35), pro-
viding a molecular basis for the observed biological effect.
Figure 6. (A,B) Docked structure of CYC (orange) in complex with Aβ(25–35) peptide (green). (A) The 
complex is displayed as ribbon and sticks and peptide interacting residues are labeled; hydrogens are omitted 
for sake of clarity. (B) The Connolly surface of the peptide and the vdW volume of CYC are displayed. (C) X-ray 
structure of the coiled-coil dimerization motif of human ROCK I protein (carbon atoms: orange; PDB ID: 
3O0Z) superimposed on the docked complex of CYC: Aβ(25–35) peptide (carbon atoms: green). Hydrogens 
are omitted for clarity. The corresponding 2-D sequence of human ROCK I protein and Aβ(25–35) are reported 
and the conserved residues of the heptad repeat motif are highlighted in bold. Molecules are colored by atom 
type (O: red; N: blue; S: yellow and H: white).
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In particular, our analyses were intended to understand whether the neuroprotective effect of the phytocom-
plex derived from Curcuma Longa can be credited to the ability of the curcuminoids to lessen lipid membrane-Aβ 
interactions and, by consequence, the Aβ-induced membrane-disruptive perturbations49–51. Accordingly, we 
investigated how curcuminoids, taken as single purified molecules, affect Aβ(25–35)− membrane interactions 
through CD and EPR experiments, using DOPC, DOPG and DOPC/DOPG liposomal solutions to mimic lipid 
bilayer membrane systems. The CD spectra of monomeric Aβ(25–35) in the different superficially charged 
liposome environments were recorded after the addition of the compounds CUR, DMC, BDMC, CYC, THC, 
HHC, OHC and MIX. These experiments were conducted to evaluate the effect of curcuminoids in solution on 
Aβ(25–35)-membrane interactions. In the presence of these curcuminoids, used pure or mixed, no significant 
modification of the Aβ(25–35) conformational equilibrium was observed in DOPC and DOPC/DOPG liposomal 
solution. In contrast, when CYC and THC were inserted into anionic DOPG lipid solution, a significant modifica-
tion of the Aβ(25–35) CD curves was detected, corresponding to a perceptible increase in the soluble form of the 
α-helix vs. β-strand and random coil conformations. These data were obtained by EPR experiments that revealed, 
for both Aβ(25–35) and curcuminoids, a shallow insertion in the DOPC, DOPC/DOPG, and DOPG lipid layers, 
just below the outer interface (5-PCLS 2Amax shift). Only in the case of CYC in DOPG liposomal solution was 
a slight but significant perturbation of 14-PCSL 2Amax observed, demonstrating that the molecule reaches the 
inner part of the bilayer. The inclusion of the curcuminoid ligands on the bilayers prevents further interaction of 
the membrane with the Aβ peptide, causing only minimal variation in the ligand-bilayer systems, with the sole 
exception of CYC in DOPG. These results are consistent with other literature data, based on TEM (transmission 
electron microscopy) images and CD spectra64, which also evidenced that the presence of CUR does not inhibit 
Aβ40 aggregation or significantly alter the morphologies of Aβ monomers, prefibrillar or fibrillar aggregates, 
while it reduces the extent of cell membrane permeabilization induced by Aβ aggregates.
In the case of DOPG membrane containing CYC or THC, the presence of the guest molecules induces a sig-
nificant alteration of the Aβ(25–35) conformational equilibrium, as observed in the CD spectra, and a marked 
perturbation of the membrane outer layer, as observed in the EPR experiments. This result may indicate a direct 
interaction of CYC and THC with Aβ(25–35), but it still cannot be excluded that the observed effects are medi-
ated by the lipid membrane. To investigate this issue, CD spectra were recorded in an HFIP/water (80/20 v:v) 
mixture in the absence and in the presence of CYC and THC. Under these conditions, CYC was still able to 
modify the conformational equilibrium of Aβ(25–35) (Fig. 3C,D), whereas THC induced only minimal modifi-
cation of the Aβ(25–35) secondary structure. Thus, THC does not directly interact with monomeric Aβ(25–35) 
in solution; nonetheless, when integrated into the DOPG system, it induces a modification in the Aβ(25–35) 
conformational equilibrium mediated by the lipid membrane. By contrast, CYC can modify the conformation 
of Aβ(25–35) either in HFIP/water solution or in anionic DOPG lipid solution, indicating that its constrained 
structure - naturally derived from an intramolecular cyclization - is suitable for direct interaction with Aβ(25–35) 
in both environments. Computational studies provided a molecular model for this interaction and a possible 
explanation for the peculiar ability of CYC, unlike CUR and THC, to interact directly with Aβ(25–35), either in 
solution or in the liposomal environment. Indeed, according to the results of our molecular modeling studies, 
this result is due to the constrained “semi-folded” conformation of CYC, which allows it to mimic the orientation 
of the hydrophobic side chains of short peptide motifs, similarly to our previous observations for other small 
ligands68,69. Thus, by mimicking the orientation of the i, i + 4, and i + 7 residues of an α -helix, CYC could interact 
with Aβ(25–35), reproducing the pattern observed in α -helical coiled-coil structures, the latter being character-
ized by the presence of one of the principal dimerization motifs in proteins70. Coiled-coil peptide structures are 
known to anchor to cellular membranes71 and are formed by heptad repeats containing hydrophobic residues at 
the “a” and “d” positions. Importantly, the formation of helical coiled-coil structures, through the reciprocal inter-
action of several heptad repeat motifs, was also observed for APP in micelles, leading to its dimerization67. In line 
with these results, our previous NMR studies evidenced a strong similarity between the structure of Aβ(1–42) 
peptide in an apolar microenvironment and the structure of the fusion domain of influenza hemagglutinin in 
detergent micelles (also characterized by the ability to form coiled-coil structures)72. A heptad repeat motif is 
still contained in the Aβ(25–35) fragment, and, similarly to previous observations, could lead to the formation 
of α -helical coiled-coil structures on the membrane lipid surface that are amenable to interaction with CYC. On 
the other hand, monomers and soluble aggregates of Aβ(25–35) in the form of α -helix are also likely to occur 
in HFIP/water solution, since, in this environment, the helical structure of Aβ(25–35) is strongly stabilized73. 
Accordingly, CYC also perturbs the conformational equilibrium of Aβ(25–35) in this environment.
The “semi-folded” conformation of CYC is poorly present in CUR (not present at all in its predominant 
keto-enol form) but still significantly present in the case of THC. However, due to the higher conformational 
flexibility of THC with respect to CYC, it represents just a fraction of the whole conformational space, with its 
relative weight depending on the polarity and the H-bond donor/acceptor properties of the solvent. Accordingly, 
CUR and other analogues characterized by a conjugated and mostly planar structure (DMC, BDMC) behave 
only as membrane stabilizers, forming ideal mixtures with DOPG lipids, reducing lipid flexibility, and preventing 
Aβ(25–35)-peptide insertion. On the contrary, CYC, which is structurally constrained in the “semi-folded” con-
formation, is able to bind/stabilize the monomeric helical form of Aβ(25–35). In this way, CYC may prevent not 
only the formation of toxic β -sheet aggregate, but also the formation of membrane disrupting aggregates formed 
by α -helical coiled-coil structures74,75. Finally, the more flexible THC shows a different behavior in DOPG bilayer 
or in the HFIP/water mixture; indeed, THC shifts the conformational equilibrium of Aβ(25–35) to the helical 
structure in DOPG, but this ability was not preserved in the HFIP/water solution.
Conclusions
The results of this work show that the well-documented biological activity of turmeric extract is based on a molec-
ular mechanism in which CUR and its analogues reduce the Aβ–membrane interactions due to their marked 
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tendency to interact with the lipid bilayer. However, this effect is differently mediated among the examined cur-
cuminoids since i) only CYC and THC can modify the conformational behavior of Aβ(25–35) in the liposome 
environment, stabilizing the α -helix conformation and ii) only CYC can still modify the conformational behavior 
of Aβ(25–35) in the HFIP/water mixture. While the enol form of CUR (“extended” conformation) was found to 
be responsible for the inhibition of Aβ fibril formation, our molecular modeling studies suggest that, to interact 
with the helical form of Aβ and prevent the formation of membrane-disrupting aggregates (possibly consisting of 
α -helical coiled-coil structures), it is necessary for CUR and its derivatives to assume the partially folded confor-
mation in which CYC is naturally constrained.
This combined approach leads to a better understanding of the intriguing in vitro and in vivo activity of cur-
cuminoids as anti-Alzheimer agents, paving a new path for the rational design of optimized druggable analogues.
Experimental Section
All reagents and solvents were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used as received. 
Curcumin was supplied from Indena S.p.A. (Milano, Italy) as mixture of curcuminoids extracted from Curcuma 
Longa. The phospholipids 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-
3-phospho-(1′ -rac-glycerol) (sodium salt) (DOPG) were purchased from Avanti Polar Lipids (Birmingham, AL, 
USA). All microwave reactions were conducted in a CEM Explorer® apparatus under monomode irradiation. 
Hydrogenation of curcuminoids was performed in a Parr® apparatus. All reactions were conducted under dry 
nitrogen atmosphere. Flash column chromatography was performed on silica gel 60, 0.040 − 0.063 mm (230–400 
mesh) using methanol/dichloromethane solvent mixtures. Silica gel (grade 60 PF254) was used for preparative 
TLC. An Agilent 1260 high-performance liquid chromatography system with a variable wavelength detector was 
used for analysis. NMR spectra were recorded on a 300 MHz NMR spectrometer using CDCl3 and MeOD as the 
solvent and TMS as the internal standard, unless otherwise specified. Conditions are specified for each spectrum 
(temperature 25 °C unless otherwise specified). Splitting patterns are designated as s, singlet; d, doublet; t, triplet; 
q, quartet; m, multiplet. Chemical shifts (δ) are given in ppm relative to the resonance of their respective residual 
solvent peak, MeOH (4.87 ppm, 1H; 49.00 ppm, the middle peak, 13C). High-resolution mass spectra (HRMS) 
were recorded on a high-resolution mass spectrometer equipped with electrospray (ESI) and nanospray sources 
and a quadrupole-time of flight hybrid analyzer coupled with a capillary UPLC system (Q-TOF Premier/nano-
Aquity, Waters) in positive mode, and protonated molecular ions [M + H]+ were used to confirm the empirical 
formula, unless otherwise stated.
Separation of curcuminoids. Liquid chromatography was performed on a Waters system 
(Milford, Massachusetts, USA) consisting of a Waters 486 Tunable Absorbance Detector and a Varian 9012 pump. 
Samples were prepared by dissolving curcuminoids (CUR, DMC, BDMC, CYC) and MIX in acetonitrile 
at 0.2 mL/min. The injection volume was 10 μ L. Curcuminoids were separated on a Teknokroma C18 column 
(25 × 0.46 cm, 5 μ m) under gradient elution at a flow rate of 0.9 mL/min. The mobile phases consisted of 2% 
(v/v) acetic acid in water (solvent A) and 2% (v/v) acetic acid in acetonitrile (solvent B). The following gradient 
was used: 0–20 min 30–70% B, 20–28 min 70–90% B, and return at initial conditions in 2 min. Detection UV at 
λ = 254 nm.
Curcumin (1). Odorless orange powder, MP: 178–180 °C; 1H NMR (300 MHz, MeOD) δ 7.58 (d, J = 15.9 Hz, 
2 H), 7.22 (s, 2 H), 7.11 (d, J = 7.4 Hz, 2 H), 6.82 (d, J = 7.7 Hz, 2 H), 6.63 (d, J = 15.7 Hz, 2 H), 5.97 (s, 1 H), 3.91 
(s, 6 H) ppm. 13C NMR (75 MHz, MeOD) δ 185.63, 151.14, 150.07, 142.71, 129.10, 124.66, 122.76, 117.01, 112.26, 
112.04, 56.50, 56.02 ppm. HRMS (ESI-Q-TOF) m/z [M + H]+ Calcd. for C21H21O6 369.1333; Found 369.1335.
Demethoxycurcumin (2). Odorless orange powder, MP: 157–161 °C; 1H NMR (300 MHz, MeOD) δ 7.52 
(dd, J = 26.6, 11.4 Hz, 4 H), 7.20 (s, 1 H), 7.09 (d, J = 7.7 Hz, 1 H), 6.81 (d, J = 7.4 Hz, 3 H), 6.73–6.49 (m, 2 H), 
3.90 (s, 3 H) ppm. 13C NMR (75 MHz, MeOD) δ 185.71, 185.51, 162.05, 151.38, 150.11, 142.68, 142.45, 131.67, 
128.94, 128.36, 124.61, 122.62, 122.36, 117.39, 117.05, 112.21, 111.99, 101.97, 56.47 ppm. HRMS (ESI-Q-TOF) 
m/z [M + H]+ Calcd. for C20H19O5 339.1227; Found 339.1230.
Bisdemethoxycurcumin (3). Odorless orange powder, MP: 187–191 °C; 1H NMR (300 MHz, MeOD) δ 7.58 
(d, J = 16.1 Hz, 3 H), 7.49 (d, J = 8.4 Hz, 4 H), 6.82 (d, J = 8.3 Hz, 5 H), 6.60 (d, J = 15.9 Hz, 2 H), 2.17 (d, J = 7.1 Hz, 3 H) 
ppm. 13C NMR (75 MHz, MeOD) δ 185.69, 161.94, 142.43, 131.67, 128.46, 122.44, 117.36. HRMS (ESI-Q-TOF) 
m/z [M + H]+ Calcd. for C19H17O4 309.1121; Found 309.1117.
Procedures for the synthesis of compounds 4, 5, 6, 7
Cyclocurcumin (4). In a 7 mL MW vessel, curcumin 1, (20 mg, 0.054 mmol) and TFA (2.14 mmol, 164 μ L) 
were added, and the reaction mixture was stirred in CEM Explorer® . MW Method: T = 100 °C, Power: 300 W, 
Hold Time: 4 min, P = 250 PSI, Power Max activated. After cooling, TFA was removed under reduced pressure, 
and the residue was purified by flash column chromatography (CH2Cl2/MeOH 97:3) to afford cyclocurcumin 4 as 
a yellowish oil (2 mg, 10%). 1H NMR (300 MHz, MeOD) δ 7.35 (d, J = 15.8 Hz, 1 H), 7.18 (s, 1 H), 7.12 (d, J = 1.7 Hz, 
1 H), 7.05 (d, J = 8.3 Hz, 1 H), 6.99 (d, J = 8.2 Hz, 1 H), 6.86 (d, J = 8.1 Hz, 1 H), 6.77 (d, J = 8.2 Hz, 1 H), 6.66 
(d, J = 15.8 Hz, 1 H), 5.62 (s, 1 H), 5.45 (dd, J = 13.7, 3.2 Hz, 1 H), 3.89 (d, J = 7.3 Hz, 6 H), 3.03 (dd, J = 16.9, 
13.8 Hz, 1 H), 2.59 (dd, J = 16.9, 3.0 Hz, 1 H). 13C NMR (75 MHz, MeOD) δ 197.20, 150.27, 143.79, 142.37, 131.77, 
124.74, 124.41, 122.41, 121.35, 119.44, 117.23, 116.70, 112.06, 111.87, 94.18, 83.43, 82.57, 56.47, 55.71 ppm. 
HRMS (ESI-Q-TOF) m/z [M + H]+ Calcd. for C21H21O6 369.1333; Found 369.1331.
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Tetrahydrocurcumin (5). A solution of curcumin 1 (50 mg, 0.14 mmol) in dry MeOH (5.9 mL) was intro-
duced into an oven-dried bottle connected to a Parr apparatus. Pt/C 10% wt (2.14 mg, 0.014 mmol) was added, 
and the bottle was filled with H2 (1 atm) and shaken at room temperature for 1 h. The bottle was degassed, and 
the catalyst was filtered (ATTENTION: the Pt residue might be pyrophoric) and washed several times with MeOH. 
The MeOH fractions were collected, and the solvent was removed under reduced pressure to give compound 
5 as a pale white oil (40 mg, 77% yield). 1H NMR (300 MHz, MeOD) δ 6.80–6.55 (m, 6 H), 3.80 (s, 6 H), 2.78 
(dd, J = 15.5, 7.6 Hz, 6 H), 2.53 (t, J = 7.5 Hz, 3 H) ppm. 13C NMR (75 MHz, MeOD) δ 195.58, 149.46, 146.42, 
134.21, 122.18, 116.55, 113.47, 56.38, 46.25, 41.27, 32.27, 29.93 ppm. HRMS (ESI-Q-TOF) m/z [M + H]+ Calcd. 
for C21H25O6 373.1646; Found 373.1648.
Hexahydrocurcumin (6) and octahydrocurcumin (7). A solution of curcumin 1 (100 mg, 0.27 mmol) 
in dry MeOH (11.8 mL) was introduced into an oven-dried bottle connected to a Parr apparatus. Pt/C 10% wt 
(5.27 mg, 0.027 mmol) was added, and the bottle was filled with H2 (6.8 atm) and shaken at room temperature 
for 13 h. The bottle was degassed, and the catalyst was filtered (ATTENTION: the Pt residue might be pyrophoric) 
and washed several times with MeOH. The MeOH fractions were collected, and the solvent was removed under 
reduced pressure to give compounds 6 and 7 as a mixture (ratio 40:60). The crude mixture was purified by flash 
column chromatography (CH2Cl2/MeOH 97:3) to afford 6 (37 mg, 37% yield) and 7 (56 mg, 55% yield) as pale 
white oils. Hexahydrocurcumin (6). 1H NMR (300 MHz, MeOD) δ 6.75 (s, 7 H), 6.69 (dd, J = 8.0, 3.0 Hz, 11 H), 
6.60 (d, J = 8.1 Hz, 11 H), 4.00 (dd, J = 11.2, 5.8 Hz, 5 H), 3.81 (d, J = 4.0 Hz, 32 H), 2.83–2.67 (m, 21 H), 2.57 (ddd, 
J = 15.7, 12.6, 6.3 Hz, 22 H), 1.68 (dd, J = 13.8, 7.6 Hz, 14 H) ppm. 13C NMR (75 MHz, MeOD) δ 212.95, 149.48, 
146.33, 146.13, 135.41, 134.56, 122.24, 122.14, 116.53, 113.56, 113.50, 68.87, 68.34, 67.80, 56.89, 56.55, 56.39, 
56.22, 51.29, 46.32, 40.37, 32.28, 30.13 ppm. HRMS (ESI-Q-TOF) m/z [M + H]+ Calcd. for C21H27O6 375.1802; 
Found 375.1805. Octahydrocurcumin (7). 1H NMR (300 MHz, MeOD) δ 6.83–6.46 (m, 3 H), 3.78 (dd, J = 20.0, 
3.4 Hz, 4 H), 2.76–2.41 (m, 2 H), 1.82–1.44 (m, 3 H) ppm. 13C NMR (75 MHz, MeOD) δ 149.44, 146.06, 135.70, 
122.22, 116.51, 113.54, 71.12, 68.83, 56.50, 44.81, 40.73, 32.21 ppm. HRMS (ESI-Q-TOF) m/z [M + H]+ Calcd. 
for C21H29O6 377.4508; Found 377.4506.
Peptide synthesis. The Aβ(25–35) peptide, (G-S-N-K-G-A-I-I-G-L-M), was manually synthesized by 
conventional solid-phase peptide synthesis (SPPS) using the Fmoc/tBu strategy76. The Nα -Fmoc-protected 
amino acids were coupled using 1-hydroxybenzotriazole and O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluroniu
mhexa-fuorophosphate (fourfold excess) as coupling reagents, in the presence of a six-fold excess of 
N,N-diisopropylethylamine. Peptide-resin (Wang resin) cleavage and side-chain deprotection reactions were 
performed in 90% trifluoroacetic acid (TFA), 5% water and 5% triisopropylsilane (TIS). The resin was filtered and 
the solution added to cold diethyl ether to precipitate the peptide.
Subsequently, the peptide was purified by reversed phase chromatography (HPLC) using a Phenomenex 
column C18 (30 cm, 4 cm, 300 Å, 15 mm spherical particle size column). The peptide was characterized on a 
Finningan LCQ Deca ion trap instrument equipped with an electrospray source (LCQ Deca Finnigan, San José. 
CA, USA). The samples were directly infused in the ESI source using a syringe pump at a flow rate of 5.0 mL/min. 
The data were analyzed using the Xcalibur software. The sample purity was > 98%.
Sample preparation for CD analysis. All CD experiments were recorded in small unilamellar liposome 
vesicles (SUVs) consisting of pure DOPC lipid, pure DOPG lipid and DOPC/DOPG mixtures at 90/10 M/M 
(molar ratio). Samples of DOPC, DOPG and DOPC/DOPG (90/10) small unilamellar liposome vesicles (SUVs) 
were prepared as follows: 200 μ M of each phospholipid were dissolved in a CH2Cl2/MeOH solution, then kept in a 
round-bottom test tube, and a thin lipid film was produced by evaporating the solvent with dry nitrogen gas. The 
final traces of solvent were removed by subjecting the sample to vacuum desiccation for one night. The samples 
were then hydrated with an appropriate volume of 10 mM phosphate buffer at pH = 7.4 and repeatedly vortexed, 
obtaining a suspension. The MLV suspension thus obtained was sonicated for 5–10 minutes to obtain SUVs.
To remove aggregate states, which can be present in Aβ samples, the dry peptide was pretreated with TFA for 
3 hours, followed by dilution with MilliQ water and lyophilization. The TFA pretreatment gives the Aβ peptide 
the properties of monomeric, random coil structures and eliminates preaggregated material77. This procedure was 
adopted for all CD samples, immediately before dissolution in the appropriate solvent. This procedure was also 
adopted before preparing Aβ(25–35) amyloid fibrils78.
To record CD experiments, Aβ(25–35) that had been previously treated according to the procedure reported 
above was added to SUVs (DOPC, DOPG and DOPC/DOPG (90/10)) to have a final peptide concentration 
of 0.1 mM (CD experiments) and a peptide-lipid molar ratio of 0.5:1 for each experiment. Similarly, ligands 
(CUR, DMC, BDMC, MIX, CYC, THC, HHC and OHC) were added to SUVs (DOPC, DOPG and DOPC/DOPG 
(90/10)) for a final ligand concentration of 0.5 mM (CD experiments).
CD measurements. Circular dichroism measurements were performed on a JASCO J-810 spectropolar-
imeter (Jasco, Cremella, Italy) equipped with a thermostated cell holder, using a quartz cell with a 1.0-mm path 
length. Spectra were collected over the wavelength range from 260–190 nm with a bandwidth of 2.0 nm and a 
time constant of 8 s.
All CD spectra were recorded in three different liposome vesicles (DOPC, DOPG and DOPC/DOPG (90/10)) 
to which Aβ(25–35) was added at a final concentration of 0.1 mM and all ligands at a final concentration of 0.5 mM. 
The CD spectrum of Aβ(25–35) in the absence of ligands was recorded for comparison. Each spectrum was cor-
rected for the contribution of the liposomes containing pure ligands. To estimate the secondary structure, the CD 
spectra were analyzed using the CONTINN, SELCON and K2D algorithms of the DICHROWEB on-line server57.
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EPR spectroscopy. For EPR experiments, multi-lamellar vesicles (MLVs) of DOPC, DOPG and DOPC/
DOPG (90/10 molar ratio) were prepared by mixing appropriate amounts of lipids, dissolved in a CH2Cl2/MeOH 
mixture (2:1 v/v, 10 mg/mL concentration), in a round-bottom test tube. Spin-labeled phosphatidylcholines 
(1-palmitoyl-2-stearoyl-(n-doxyl)-sn-glycero-3-phosphocholine, n-PCSL with n = 5, 14) were added to the lipid 
mixture (1% by weight of the total lipid) by mixing appropriate amounts of a spin-label solution in ethanol (1 mg/
mL) with the lipid organic mixture. A thin lipid film was produced by evaporating the solvents with dry nitrogen 
gas. The total weight of the lipids for each sample was 0.2 mg. The final traces of solvents were removed by sub-
jecting the sample to vacuum desiccation for at least 3 h. The samples were then hydrated with 20 μ L of 10 mM 
phosphate buffer at pH = 7.4, gently warmed and repeatedly vortexed to obtain a MLV suspension.
Samples containing curcumin or one of its analogues were prepared by the same procedure, adding appropri-
ate amounts of the flavonoid dissolved in DMSO (10 mg/mL) to the buffer during the re-hydration step to obtain 
a 0.5 molar percentage with respect to the total lipids. The addition of DMSO was preventively checked to result 
in no perturbation of the vesicular systems.
Samples containing Aβ(25–35) were prepared in a similar manner, except that the lipid film was hydrated 
directly with the peptide solution in phosphate buffer, at 1:0.5 lipid/peptide weight ratio (which corresponds to 
approximately 20:1 mol/mol).
EPR spectra were recorded with a 9 GHz Bruker Elexys E-500 spectrometer (Bruker, Rheinstetten, Germany). 
Samples were placed in 25 μ L glass capillaries and flame sealed. The capillaries were placed in a standard 4 mm 
quartz sample tube containing light silicone oil for thermal stability. All measurements were performed at 25 °C. 
The spectra were recorded using the following instrumental settings: sweep width, 100 G; resolution, 1024 points; 
time constant, 20.48 ms; modulation frequency, 100 kHz; modulation amplitude, 1.0 G; incident power, 6.37 mW. 
Several scans, typically 16, were accumulated to improve the signal-to-noise ratio.
Molecular modeling. Molecular modeling calculations were performed on an SGI Origin 200 8XR12000 
and an E4 Server Twin 2 x Dual Xeon 5520, equipped with two nodes. Each node was 2 x Intel Xeon QuadCore 
E5520, 2.26 GHz, 36 GB RAM. The molecular modeling graphics were implemented on SGI Octane 2 
workstations.
The apparent pKa values of CUR and its derivatives in their tautomeric forms were estimated using the ACD/
Percepta software79. Accordingly, the percentages of neutral/ionized forms were computed at pH 7.2 (cytoplasm) 
using the Henderson-Hasselbach equation.
Conformational analysis. All compounds were built considering the prevalent ionic forms of each tautomer 
using the Insight 2005 Builder module (Accelrys Software, Inc., San Diego).
Atomic potentials and partial charges were assigned using the CVFF force field80. The conformational space 
of the compounds was sampled through 200 cycles of simulated annealing (ε = 80*r). To avoid unrealistic results, 
the torsional angle of the double bonds was constrained within 180° using a force constant of 100 (kcal/mol)/Å. 
In simulated annealing, the temperature is altered in time increments from an initial temperature to a final tem-
perature by adjusting the kinetic energy of the structure (by rescaling the velocities of the atoms). The following 
protocol was applied: the system was heated to 1000 K over 2000 fs (time step of 3.0 fs); the temperature of 1000 K 
was applied to the system for 2000 fs (time step of 3.0 fs) to surmount torsional barriers; then, the temperature 
was linearly reduced to 300 K in 1000 fs (time step of 1.0 fs). The resulting conformations were then subjected 
to Molecular Mechanics (MM) energy minimization within the Insight 2005 Discover 3 module (CVFF force 
field; ε = 80*r) until the maximum RMS derivative was less than 0.001 kcal/Å, using the conjugate gradient81 as 
the minimization algorithm. The resulting MM conformers were ranked by (i) their potential energy values (i.e., 
Δ E from the global energy minimum), (ii) intra-molecular hydrogen bonds, (iii) torsional angles, and (iv) the 
interatomic distance between the centroids of the two aromatic rings. The centroids were determined considering 
the heavy atoms of the aromatic rings (Pseudo_Atom Define command, Biopolymer Module, Insight 2005). Then, 
the occurrence rates were calculated.
All MM conformers were subjected to a full geometric optimization by semi-empirical calculations, using the 
quantum mechanical method PM782 in the MOPAC2012 package82 and EF83 (eigenvector following routine) as 
the geometric optimization algorithm. The GNORM value was set to 0.01. To achieve full geometric optimization, 
the criterion for terminating all optimizations was increased by a factor of 100, using the keyword PRECISE. The 
resulting PM7 conformers were ranked as MM conformers.
Finally, the X-ray structures of CUR, alone (CSD codes: AXOGIE, AXOGOK, BINMEQ, BINMEQ01, 
BINMEQ02, BINMEQ03, BINMEQ04, BINMEQ05, BINMEQ06, BINMEQ07, BINMEQ08, BUWKUZ, 
GANJAG) or in complex with any metal (CSD code: RAWDOK), were selected and downloaded from the 
Cambridge Structural Database (CSD) using the CSDS (Cambridge Structural Database System) software 
Conquest 1.16. These structures were analyzed using Insight 2005 (Accelrys, San Diego, CA).
Docking procedure. To build the starting complex CYC:Aβ(25–35) for dynamic docking studies, the experi-
mentally determined structure of Aβ(25–35) (PDB ID: 1QWP) was downloaded from the Protein Data Bank 
(PDB; http://www.rcsb.org/pdb/). Hydrogens were added to the PDB structure assuming a pH of 7.2. This struc-
ture was analyzed and compared with the experimentally determined structures of HDM2 protein in complex 
with p53 (PDB ID: 1YCR), using the Biopolymer and Homology module of Insight 2005 (Accelrys, San Diego). 
Accordingly, a structural superimposition was performed between the α -helix of HDM2 (A50-A65) and Aβ 
(25–35). The centroids of interacting residues of considered LxxLLxxL-like (i, i + 3, i + 4, i + 7) motif (B17-B29; 
PDB ID: 1YCR) were built, and their relative distances were calculated. The resulting values were crossed with 
the values of the CYC pharmacophore distances. The lowest-energy PM7 conformer of CYC was superimposed 
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on residues i and i + 4 (i.e., Phe19 and Trp23) of the LxxLLxxL-like motif by fitting the centroids of the aromatic 
rings (i.e., X and Y) on the centroids of the side chains of the corresponding residues. Then, the resulting struc-
ture of the complex CYC: Aβ(25–35) was used for successive dynamic docking studies. In particular, a dock-
ing methodology was used that treats all the systems (i.e., ligand and protein) as flexible. Flexible docking was 
achieved using the Affinity module in the Insight 2005 suite, setting the SA_Docking procedure84 and using the 
Cell Multipole method for nonbonding interactions85. To mimic the experimental conditions (a mixture of HFIP 
and water; 80/20 v:v), throughout the calculations, a dielectric constant of 30*r was used. This value was obtained 
as the weighted average of the dielectric constants of water (ε = 80) and HFIP (ε = 16.7).
The docking protocol included a Monte Carlo-based conformational search of the ligand (CYC) within the 
Aβ(25–35) peptide. The binding domain area was defined as a subset including all residues of the Aβ(25–35) pep-
tide. All atoms included in the binding domain area were left free to move throughout the course of the docking 
calculations, whereas to avoid unrealistic results, a tethering restraint was applied to the SCRs of the protein. In 
particular, for the α -helix Asn27-Leu34, the distance between backbone hydrogen bond donors and acceptors 
was restrained within 2.5 Å using a force constant of 10 kcal/mol/Å2.
A Monte Carlo/minimization approach for the random generation of a maximum of 20 acceptable com-
plexes was used. During the first step, starting from the previously obtained roughly docked structures, the 
ligand was moved by a random combination of translation, rotation, and torsional changes to sample both 
the conformational space of the ligand and its orientation with respect to the protein (MxRChange = 3 Å; 
MxAngChange = 180°). During this step, the van der Waals (vdW) and Columbic terms were scaled to a factor 
of 0.1 to avoid very severe divergences in the vdW and Columbic energies. If the energy of a complex structure 
resulting from random moves of the ligand was higher by the energy tolerance parameter than the energy of the 
last accepted structure, it was not accepted for minimization. To ensure a wide variance in the input structures to 
be successively minimized, an energy tolerance value of 106 kcal/mol from the previous structure was used. After 
the energy minimization step (conjugate gradient; 10000 iterations; ε = 30*r), the energy test, using an energy 
range of 50 kcal/mol, and a structure similarity check (rms tolerance = 0.3 kcal/Å) were applied to select the 20 
acceptable structures. Each subsequent structure was generated from the last accepted structure. Following this 
procedure, the resulting docked structures were ranked by their conformational energy and analyzed. Finally, to 
test the thermodynamic stability of the resulting docked complexes; these latter were subjected also to a molecular 
dynamics simulated annealing protocol (ε = 30*r). A tethering restraint was applied to the SCRs of the complex. 
The same set of structural restraints used for previous docking calculations was applied. The protocol included 
5 ps of a dynamic run divided into 50 stages (100 fs each), during which the temperature of the system was linearly 
decreased from 500 to 300 K (Verlet velocity integrator; time step = 1.0 fs). In simulated annealing, the tempera-
ture is altered in time increments from an initial temperature to a final temperature. The temperature is changed 
by adjusting the kinetic energy of the structure (by rescaling the velocities of the atoms). Molecular dynamics 
calculations were performed using a constant temperature and constant volume (NVT) statistical ensemble, with 
direct velocity scaling as the temperature control method (temp window = 10 K). In the first stage, the initial 
velocities were randomly generated from the Boltzmann distribution, according to the desired temperature, while 
during the subsequent stages, the initial velocities were generated from the dynamics restart data. A tempera-
ture of 500 K was applied to surmount torsional barriers, thus allowing an unconstrained rearrangement of the 
“ligand” and the “protein” active site (initial vdW and Columbic scale factors = 0.1). The temperature was then 
linearly reduced to 300 K in 5 ps, and, concurrently, the vdW and Columbic scale factors were similarly increased 
from their initial values (0.1) to their final values (1.0). A final round of 105 minimization steps (ε = 30*r) followed 
the last dynamics steps, and the minimized structures were saved in a trajectory file.
The resulting complexes were ranked by their conformational energy and analyzed by considering the 
non-bond interaction energies between the ligand and the peptide (vdW and electrostatic energy contribution; 
Group Based method; CUT_OFF = 100; ε = 2*r; Discover_3 Module of Insight2005). The complex characterized 
by the lowest conformational and interaction energy was chosen as the most representative. To allow the relaxa-
tion of the whole system, this complex was further minimized with no tethering restraint (CVFF force field; Cell 
Multipole method for non-bond interaction) using the Conjugate Gradient algorithm (maximum rms derivative 
less than 0.01 kcal/Å). Finally, the selected complex was compared with the experimentally determined structures 
of i) HDM2 protein in complex with p53 (PDB ID: 1YCR), ii) estrogen receptor β in complex with the nuclear 
receptor coactivator 5 (Ncoa5; PDB ID: 2J7X), iii) the coiled-coil dimerization motif of Geminin (PDB ID: 1T6F), 
and iv) the coiled-coil dimerization motif of the human ROCK I protein (PDB ID: 3O0Z) using the Biopolymer 
and Homology module of Insight 2005 (Accelrys, San Diego).
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